Since in both group 1 and group 2 hypertension was reported as the most frequent comorbidity and we did not use comorbidity as criteria for matching healthy and COVID-19 patients, we tested if the anti-hypertensive drug more used in group 2, the angiotensin- angiotensin-converting enzyme (ACE) inhibitor ramipril, could affect NET-osis. The gene discussed is ACE; the disease is COVID-19.